Alphamab Oncology
Alphamab Oncology, a leading biopharmaceutical company headquartered in China, is at the forefront of innovative cancer therapies. Founded in 2016, the company has rapidly established itself in the oncology sector, focusing on the research, development, and commercialisation of monoclonal antibodies and other biologics. With a strong presence in both domestic and international markets, Alphamab Oncology has achieved significant milestones, including the successful development of its proprietary drug candidates. Their core products, distinguished by their unique mechanisms of action, aim to address unmet medical needs in cancer treatment. Recognised for its commitment to advancing oncology solutions, Alphamab Oncology continues to strengthen its market position through strategic partnerships and a robust pipeline, making it a notable player in the global biopharmaceutical landscape.
DitchCarbon Score
How does Alphamab Oncology's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Alphamab Oncology's score of 22 is lower than 71% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Alphamab Oncology's reported carbon emissions
In 2024, Alphamab Oncology reported total carbon emissions of approximately 13,821,490 kg CO2e, comprising 4,022,890 kg CO2e from Scope 1 and 9,798,600 kg CO2e from Scope 2 emissions. This marks a slight increase from 2023, where emissions totalled about 12,760,800 kg CO2e, with Scope 1 emissions at 3,969,510 kg CO2e and Scope 2 emissions at 8,791,300 kg CO2e. Over the past few years, Alphamab has demonstrated a commitment to monitoring and reporting its emissions, although no specific reduction targets or climate pledges have been established. The company has not disclosed any Scope 3 emissions data, indicating a potential area for future focus. Alphamab's emissions data is not cascaded from any parent organization, and all reported figures are derived directly from its own operations. The company continues to engage in industry-standard practices for emissions reporting, contributing to transparency in its environmental impact.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 75,810 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 798,260 | 00,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Alphamab Oncology is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
